

Supplementary Information

Pentacyclic Triterpenes from Branches of *Maytenus robusta* and *in vitro* Cytotoxic Property Against 4T1 Cancer Cells

Grasiely Faria de Sousa,^a Daniel Crístian Ferreira Soares,^b Wagner da Nova Mussel,^a
Nana Flora Elias Pompeu,^a Grácia Divina de Fátima Silva,^a
Sidney Augusto Vieira Filho^c and Lucienir Pains Duarte^{*a}

^aDepartamento de Química, Universidade Federal de Minas Gerais,
Avenida Presidente Antônio Carlos, 6627, Pampulha, 31270-901 Belo Horizonte-MG, Brazil

^bUniversidade Federal de Itajubá, Campus Itabira, Rua Irmã Ivone Drumond, 200,
Distrito Industrial II, 35903-087 Itabira-MG, Brazil

^cEscola de Farmácia, Universidade Federal de Ouro Preto,
Rua Costa Sena, 171, Centro, 35400-000 Ouro Preto-MG, Brazil




Figure S1. ¹H NMR spectrum of compound 1 (CDCl₃ + Py-*d*₅, 400 MHz).




Figure S2. ^1H NMR spectrum of compound **1** (region of 1.4 to 0 ppm and 0.91 to 0.84 ppm, $\text{CDCl}_3 + \text{Py}-d_5$, 400 MHz).




Figure S3. ^{13}C NMR spectrum of compound **1** ($\text{CDCl}_3 + \text{Py}-d_5$, 100 MHz).




Figure S4. Subspectrum DEPT135 of compound **1** (CDCl_3 + $\text{Py}-d_5$, 100 MHz).




Figure S5. HSQC correlation of compound **1** (CDCl_3 + $\text{Py}-d_5$, 400 MHz).




Figure S6. HMBC correlation of compound **1** ($\text{CDCl}_3 + \text{Py}-d_5$, 400 MHz).




Figure S7. HMBC correlation of compound **1** (region of 2.8 to 0.5 ppm, $\text{CDCl}_3 + \text{Py}-d_5$, 400 MHz).




Figure S8. COSY correlation of compound **1** (CDCl_3 + $\text{Py}-d_5$, 400 MHz).




Figure S9. NOESY correlation of compound **1** (CDCl_3 + $\text{Py}-d_5$, 400 MHz).




Figure S10. IR spectrum of compound 1 (ATR).




Figure S11. TG, DTG and DTA thermal curves of 1.




Figure S12. HR-APCIMS (positive-ion mode) spectrum of compound 1.




Figure S13. ¹H NMR spectrum of compound 2 (CDCl₃ + Py-d₅, 400 MHz).




Figure S14. ¹H NMR spectrum of compound 2 (region of 1.32 to 0 ppm, CDCl₃ + Py-*d*₅, 400 MHz).




Figure S15. ¹³C NMR spectrum of compound 2 (CDCl₃ + Py-*d*₅, 100 MHz).




Figure S16. Subspectrum DEPT135 of compound **2** ($\text{CDCl}_3 + \text{Py}-d_5$, 100 MHz).




Figure S17. HSQC correlation of compound **2** ($\text{CDCl}_3 + \text{Py}-d_5$, 400 MHz).




Figure S18. HSQC correlation of compound 2 (region of 4.2 to 3.3 ppm CDCl_3 + $\text{Py}-d_5$, 400 MHz).




Figure S19. HMBC correlation of compound 2 (CDCl_3 + $\text{Py}-d_5$, 400 MHz).




Figure S20. HMBC correlation of compound 2 (region of 4.2 to 3.3 ppm CDCl₃ + Py-*d*₅, 400 MHz).




Figure S21. HMBC correlation of compound 2 (region of 2.4 to 0.6 ppm CDCl₃ + Py-*d*₅, 400 MHz).




Figure S22. COSY correlation of compound 2 (CDCl₃ + Py-d₅, 400 MHz).




Figure S23. NOESY correlation of compound 2 (CDCl₃ + Py-d₅, 400 MHz).




Figure S24. NOESY correlation of compound **2** (region of 4.2 to 3.3 ppm, $\text{CDCl}_3 + \text{Py}-d_5$, 400 MHz).




Figure S25. IR spectrum of compound **2** (ATR).




Figure S26. TG, DTG and DTA thermal curves of **2**.




Figure S27. HR-APCIMS (positive-ion mode) spectrum of compound **2**.